External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients

Objectives In patients with essential thrombocythemia (ET), vascular complications contribute to both morbidity and mortality. To better predict the occurrence of thrombotic events, an International Prognostic Score of thrombosis for ET (IPSET‐thrombosis) was recently developed. We hereby presented...

Full description

Saved in:
Bibliographic Details
Published in:European journal of haematology 2014-06, Vol.92 (6), p.502-509
Main Authors: Fu, Rongfeng, Xuan, Min, Lv, Cuicui, Zhang, Liyan, Li, Huiyuan, Zhang, Xian, Zhang, Donglei, Sun, Tiantian, Xue, Feng, Liu, Xiaofan, Liang, Haoyue, Zhang, Lei, Yang, Renchi
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Female
Follow-Up Studies
Humans
Incidence
Male
Middle Aged
primary thrombocythemia
Prognosis
Risk Factors
Thrombocythemia, Essential - complications
Thrombocythemia, Essential - diagnosis
Thrombocythemia, Essential - mortality
Thrombocythemia, Essential - therapy
thrombosis
Thrombosis - epidemiology
Thrombosis - etiology
Thrombosis - therapy
treatment
Young Adult
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 509
container_issue 6
container_start_page 502
container_title European journal of haematology
container_volume 92
creator Fu, Rongfeng
Xuan, Min
Lv, Cuicui
Zhang, Liyan
Li, Huiyuan
Zhang, Xian
Zhang, Donglei
Sun, Tiantian
Xue, Feng
Liu, Xiaofan
Liang, Haoyue
Zhang, Lei
Yang, Renchi
description Objectives In patients with essential thrombocythemia (ET), vascular complications contribute to both morbidity and mortality. To better predict the occurrence of thrombotic events, an International Prognostic Score of thrombosis for ET (IPSET‐thrombosis) was recently developed. We hereby presented an external validation and analysis of this model in a large Cohort of Chinese Patients. Methods We retrospectively evaluated the characteristics and risk factors for thrombosis in 970 Chinese patients with ET and estimated the clinical implications of the IPSET‐thrombosis model. Results The median follow‐up was 49 months (range, 0–360). Chinese ET patients had similar clinical characteristics as Caucasian patients. Similar to the IPSET‐thrombosis study, our multivariate analysis revealed age >60 (HR = 1.949), previous thrombosis (HR = 2.484), JAK2V617F mutation (HR = 1.719), and cardiovascular risk factors (HR = 1.877) as independent risk factors for thrombosis. We confirmed that the above risk factors in IPSET‐thrombosis, when compared with traditional risk factors (e.g., age ≥60 and previous thrombotic events), were more predictive of thrombotic events (C‐index 0.714 vs. 0.647). Classification by IPSET‐thrombosis risk groups revealed different cumulative thrombosis‐free survival (P 
doi_str_mv 10.1111/ejh.12275
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1525767290</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1525767290</sourcerecordid><originalsourceid>FETCH-LOGICAL-i3555-4e4de8384caec387a56ef615f5e2ca45a50fca6c55a6d958f3a5e83b152c35163</originalsourceid><addsrcrecordid>eNo9kc1OGzEUha2qVUmBRV-g8pIuBuwZ25NZVtE0BCEKJdCl5XjuMKYzdmo7LXkxng_np_HG1jnfOVfyRegzJec0nQt47s5pnpf8HRpRQUhGBKneoxGpSJ4xxugR-hTCMyEkr2j5ER3ljAlScjJCr_VLBG9Vj_-q3jQqGmexsg3WvbFGJx2SsdrprsWxAzyz28hGSv6td0_WhWg0vtfOw4aad94NCxdMwK3zuA4BbDQJ3ht6nXoGo_DZ7Pa-nmfxwH_FJs3HvfJPgLXrnI-bwklnLATAyzQ1VYUT9KFVfYDT_X2MHr7X88lldv1jOpt8u85MwTnPGLAGxsWYaQW6GJeKC2gF5S2HXCvGFSetVkJzrkRT8XFbKJ74BeW5LjgVxTE62_UuvfuzghDlYIKGvlcW3CrIBPJSlHlFEvplj64WAzRy6c2g_Fr-_-sEXOyAf6aH9cGnRG6WKNMS5XaJsr663D5SItslTIjwckgo_1uKskjkr5upvPs5vXtk-Y28Kt4AfnKhqQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1525767290</pqid></control><display><type>article</type><title>External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients</title><source>Wiley</source><creator>Fu, Rongfeng ; Xuan, Min ; Lv, Cuicui ; Zhang, Liyan ; Li, Huiyuan ; Zhang, Xian ; Zhang, Donglei ; Sun, Tiantian ; Xue, Feng ; Liu, Xiaofan ; Liang, Haoyue ; Zhang, Lei ; Yang, Renchi</creator><creatorcontrib>Fu, Rongfeng ; Xuan, Min ; Lv, Cuicui ; Zhang, Liyan ; Li, Huiyuan ; Zhang, Xian ; Zhang, Donglei ; Sun, Tiantian ; Xue, Feng ; Liu, Xiaofan ; Liang, Haoyue ; Zhang, Lei ; Yang, Renchi</creatorcontrib><description>Objectives In patients with essential thrombocythemia (ET), vascular complications contribute to both morbidity and mortality. To better predict the occurrence of thrombotic events, an International Prognostic Score of thrombosis for ET (IPSET‐thrombosis) was recently developed. We hereby presented an external validation and analysis of this model in a large Cohort of Chinese Patients. Methods We retrospectively evaluated the characteristics and risk factors for thrombosis in 970 Chinese patients with ET and estimated the clinical implications of the IPSET‐thrombosis model. Results The median follow‐up was 49 months (range, 0–360). Chinese ET patients had similar clinical characteristics as Caucasian patients. Similar to the IPSET‐thrombosis study, our multivariate analysis revealed age &gt;60 (HR = 1.949), previous thrombosis (HR = 2.484), JAK2V617F mutation (HR = 1.719), and cardiovascular risk factors (HR = 1.877) as independent risk factors for thrombosis. We confirmed that the above risk factors in IPSET‐thrombosis, when compared with traditional risk factors (e.g., age ≥60 and previous thrombotic events), were more predictive of thrombotic events (C‐index 0.714 vs. 0.647). Classification by IPSET‐thrombosis risk groups revealed different cumulative thrombosis‐free survival (P &lt; 0.001). For treatment, patients in the intermediate‐ and high‐risk group derived clinical benefit from cytoreductive agents (P &lt; 0.05), but those in the low‐risk group did not (P = 0.446). The lower risk of thrombosis on cytoreductive therapy was related to decrease in leukocyte count during the disease course. Conclusions We validate the reproducibility of IPSET‐thrombosis in Chinese ET patients and provide key clinical implications.</description><identifier>ISSN: 0902-4441</identifier><identifier>EISSN: 1600-0609</identifier><identifier>DOI: 10.1111/ejh.12275</identifier><identifier>PMID: 24460750</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Female ; Follow-Up Studies ; Humans ; Incidence ; Male ; Middle Aged ; primary thrombocythemia ; Prognosis ; Risk Factors ; Thrombocythemia, Essential - complications ; Thrombocythemia, Essential - diagnosis ; Thrombocythemia, Essential - mortality ; Thrombocythemia, Essential - therapy ; thrombosis ; Thrombosis - epidemiology ; Thrombosis - etiology ; Thrombosis - therapy ; treatment ; Young Adult</subject><ispartof>European journal of haematology, 2014-06, Vol.92 (6), p.502-509</ispartof><rights>2014 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd</rights><rights>2014 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24460750$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fu, Rongfeng</creatorcontrib><creatorcontrib>Xuan, Min</creatorcontrib><creatorcontrib>Lv, Cuicui</creatorcontrib><creatorcontrib>Zhang, Liyan</creatorcontrib><creatorcontrib>Li, Huiyuan</creatorcontrib><creatorcontrib>Zhang, Xian</creatorcontrib><creatorcontrib>Zhang, Donglei</creatorcontrib><creatorcontrib>Sun, Tiantian</creatorcontrib><creatorcontrib>Xue, Feng</creatorcontrib><creatorcontrib>Liu, Xiaofan</creatorcontrib><creatorcontrib>Liang, Haoyue</creatorcontrib><creatorcontrib>Zhang, Lei</creatorcontrib><creatorcontrib>Yang, Renchi</creatorcontrib><title>External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients</title><title>European journal of haematology</title><addtitle>Eur J Haematol</addtitle><description>Objectives In patients with essential thrombocythemia (ET), vascular complications contribute to both morbidity and mortality. To better predict the occurrence of thrombotic events, an International Prognostic Score of thrombosis for ET (IPSET‐thrombosis) was recently developed. We hereby presented an external validation and analysis of this model in a large Cohort of Chinese Patients. Methods We retrospectively evaluated the characteristics and risk factors for thrombosis in 970 Chinese patients with ET and estimated the clinical implications of the IPSET‐thrombosis model. Results The median follow‐up was 49 months (range, 0–360). Chinese ET patients had similar clinical characteristics as Caucasian patients. Similar to the IPSET‐thrombosis study, our multivariate analysis revealed age &gt;60 (HR = 1.949), previous thrombosis (HR = 2.484), JAK2V617F mutation (HR = 1.719), and cardiovascular risk factors (HR = 1.877) as independent risk factors for thrombosis. We confirmed that the above risk factors in IPSET‐thrombosis, when compared with traditional risk factors (e.g., age ≥60 and previous thrombotic events), were more predictive of thrombotic events (C‐index 0.714 vs. 0.647). Classification by IPSET‐thrombosis risk groups revealed different cumulative thrombosis‐free survival (P &lt; 0.001). For treatment, patients in the intermediate‐ and high‐risk group derived clinical benefit from cytoreductive agents (P &lt; 0.05), but those in the low‐risk group did not (P = 0.446). The lower risk of thrombosis on cytoreductive therapy was related to decrease in leukocyte count during the disease course. Conclusions We validate the reproducibility of IPSET‐thrombosis in Chinese ET patients and provide key clinical implications.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Middle Aged</subject><subject>primary thrombocythemia</subject><subject>Prognosis</subject><subject>Risk Factors</subject><subject>Thrombocythemia, Essential - complications</subject><subject>Thrombocythemia, Essential - diagnosis</subject><subject>Thrombocythemia, Essential - mortality</subject><subject>Thrombocythemia, Essential - therapy</subject><subject>thrombosis</subject><subject>Thrombosis - epidemiology</subject><subject>Thrombosis - etiology</subject><subject>Thrombosis - therapy</subject><subject>treatment</subject><subject>Young Adult</subject><issn>0902-4441</issn><issn>1600-0609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNo9kc1OGzEUha2qVUmBRV-g8pIuBuwZ25NZVtE0BCEKJdCl5XjuMKYzdmo7LXkxng_np_HG1jnfOVfyRegzJec0nQt47s5pnpf8HRpRQUhGBKneoxGpSJ4xxugR-hTCMyEkr2j5ER3ljAlScjJCr_VLBG9Vj_-q3jQqGmexsg3WvbFGJx2SsdrprsWxAzyz28hGSv6td0_WhWg0vtfOw4aad94NCxdMwK3zuA4BbDQJ3ht6nXoGo_DZ7Pa-nmfxwH_FJs3HvfJPgLXrnI-bwklnLATAyzQ1VYUT9KFVfYDT_X2MHr7X88lldv1jOpt8u85MwTnPGLAGxsWYaQW6GJeKC2gF5S2HXCvGFSetVkJzrkRT8XFbKJ74BeW5LjgVxTE62_UuvfuzghDlYIKGvlcW3CrIBPJSlHlFEvplj64WAzRy6c2g_Fr-_-sEXOyAf6aH9cGnRG6WKNMS5XaJsr663D5SItslTIjwckgo_1uKskjkr5upvPs5vXtk-Y28Kt4AfnKhqQ</recordid><startdate>201406</startdate><enddate>201406</enddate><creator>Fu, Rongfeng</creator><creator>Xuan, Min</creator><creator>Lv, Cuicui</creator><creator>Zhang, Liyan</creator><creator>Li, Huiyuan</creator><creator>Zhang, Xian</creator><creator>Zhang, Donglei</creator><creator>Sun, Tiantian</creator><creator>Xue, Feng</creator><creator>Liu, Xiaofan</creator><creator>Liang, Haoyue</creator><creator>Zhang, Lei</creator><creator>Yang, Renchi</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201406</creationdate><title>External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients</title><author>Fu, Rongfeng ; Xuan, Min ; Lv, Cuicui ; Zhang, Liyan ; Li, Huiyuan ; Zhang, Xian ; Zhang, Donglei ; Sun, Tiantian ; Xue, Feng ; Liu, Xiaofan ; Liang, Haoyue ; Zhang, Lei ; Yang, Renchi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i3555-4e4de8384caec387a56ef615f5e2ca45a50fca6c55a6d958f3a5e83b152c35163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Middle Aged</topic><topic>primary thrombocythemia</topic><topic>Prognosis</topic><topic>Risk Factors</topic><topic>Thrombocythemia, Essential - complications</topic><topic>Thrombocythemia, Essential - diagnosis</topic><topic>Thrombocythemia, Essential - mortality</topic><topic>Thrombocythemia, Essential - therapy</topic><topic>thrombosis</topic><topic>Thrombosis - epidemiology</topic><topic>Thrombosis - etiology</topic><topic>Thrombosis - therapy</topic><topic>treatment</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fu, Rongfeng</creatorcontrib><creatorcontrib>Xuan, Min</creatorcontrib><creatorcontrib>Lv, Cuicui</creatorcontrib><creatorcontrib>Zhang, Liyan</creatorcontrib><creatorcontrib>Li, Huiyuan</creatorcontrib><creatorcontrib>Zhang, Xian</creatorcontrib><creatorcontrib>Zhang, Donglei</creatorcontrib><creatorcontrib>Sun, Tiantian</creatorcontrib><creatorcontrib>Xue, Feng</creatorcontrib><creatorcontrib>Liu, Xiaofan</creatorcontrib><creatorcontrib>Liang, Haoyue</creatorcontrib><creatorcontrib>Zhang, Lei</creatorcontrib><creatorcontrib>Yang, Renchi</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fu, Rongfeng</au><au>Xuan, Min</au><au>Lv, Cuicui</au><au>Zhang, Liyan</au><au>Li, Huiyuan</au><au>Zhang, Xian</au><au>Zhang, Donglei</au><au>Sun, Tiantian</au><au>Xue, Feng</au><au>Liu, Xiaofan</au><au>Liang, Haoyue</au><au>Zhang, Lei</au><au>Yang, Renchi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients</atitle><jtitle>European journal of haematology</jtitle><addtitle>Eur J Haematol</addtitle><date>2014-06</date><risdate>2014</risdate><volume>92</volume><issue>6</issue><spage>502</spage><epage>509</epage><pages>502-509</pages><issn>0902-4441</issn><eissn>1600-0609</eissn><abstract>Objectives In patients with essential thrombocythemia (ET), vascular complications contribute to both morbidity and mortality. To better predict the occurrence of thrombotic events, an International Prognostic Score of thrombosis for ET (IPSET‐thrombosis) was recently developed. We hereby presented an external validation and analysis of this model in a large Cohort of Chinese Patients. Methods We retrospectively evaluated the characteristics and risk factors for thrombosis in 970 Chinese patients with ET and estimated the clinical implications of the IPSET‐thrombosis model. Results The median follow‐up was 49 months (range, 0–360). Chinese ET patients had similar clinical characteristics as Caucasian patients. Similar to the IPSET‐thrombosis study, our multivariate analysis revealed age &gt;60 (HR = 1.949), previous thrombosis (HR = 2.484), JAK2V617F mutation (HR = 1.719), and cardiovascular risk factors (HR = 1.877) as independent risk factors for thrombosis. We confirmed that the above risk factors in IPSET‐thrombosis, when compared with traditional risk factors (e.g., age ≥60 and previous thrombotic events), were more predictive of thrombotic events (C‐index 0.714 vs. 0.647). Classification by IPSET‐thrombosis risk groups revealed different cumulative thrombosis‐free survival (P &lt; 0.001). For treatment, patients in the intermediate‐ and high‐risk group derived clinical benefit from cytoreductive agents (P &lt; 0.05), but those in the low‐risk group did not (P = 0.446). The lower risk of thrombosis on cytoreductive therapy was related to decrease in leukocyte count during the disease course. Conclusions We validate the reproducibility of IPSET‐thrombosis in Chinese ET patients and provide key clinical implications.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>24460750</pmid><doi>10.1111/ejh.12275</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0902-4441
ispartof European journal of haematology, 2014-06, Vol.92 (6), p.502-509
issn 0902-4441
1600-0609
language eng
recordid cdi_proquest_miscellaneous_1525767290
source Wiley
subjects Adolescent
Adult
Aged
Female
Follow-Up Studies
Humans
Incidence
Male
Middle Aged
primary thrombocythemia
Prognosis
Risk Factors
Thrombocythemia, Essential - complications
Thrombocythemia, Essential - diagnosis
Thrombocythemia, Essential - mortality
Thrombocythemia, Essential - therapy
thrombosis
Thrombosis - epidemiology
Thrombosis - etiology
Thrombosis - therapy
treatment
Young Adult
title External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A02%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=External%20validation%20and%20clinical%20evaluation%20of%20the%20International%20Prognostic%20Score%20of%20Thrombosis%20for%20Essential%20Thrombocythemia%20(IPSET-thrombosis)%20in%20a%20large%20cohort%20of%20Chinese%20patients&rft.jtitle=European%20journal%20of%20haematology&rft.au=Fu,%20Rongfeng&rft.date=2014-06&rft.volume=92&rft.issue=6&rft.spage=502&rft.epage=509&rft.pages=502-509&rft.issn=0902-4441&rft.eissn=1600-0609&rft_id=info:doi/10.1111/ejh.12275&rft_dat=%3Cproquest_pubme%3E1525767290%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-i3555-4e4de8384caec387a56ef615f5e2ca45a50fca6c55a6d958f3a5e83b152c35163%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1525767290&rft_id=info:pmid/24460750&rfr_iscdi=true